Back to the main directory
EarningsReview / Equity
- BBVA - Stronger 1Q25 and capital beat are positive by JB Capital Markets
- 1Q25 Trading Statement: softer growth but guidance reiterated by BNP Paribas Exane
- Q1’25 results: Some weakness below the surface by BNP Paribas Exane
- Magin improvement but cash outflow, leverage rises to 38% by BNP Paribas Exane
- 1Q25 results - Beat driven by costs and provisions by BNP Paribas Exane
- Chargeurs - Solide début d’année by MidCap Partners
- Bigben - FY24 by MidCap Partners
- Nacon - Solide by MidCap Partners
- VISCOFAN: RDOS. 1T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- Q1 fine but not enough. Guidance reiterated by BNP Paribas Exane
- Positive call on guidance despite macro headwinds by BNP Paribas Exane
- INVEST SECURITIES - AIRWELL : Optimisme affiché dès le T2 2025 à confirmer - ACHAT, OC 3,6€ vs 4,0€ by Invest Securities
- Bigben - FY24 by MidCap Partners
- Nacon - Solid by MidCap Partners
- SMCP - Strong performance by MidCap Partners
- INVEST SECURITIES - TME PHARMA : Visibilité à juin 2025, structuration 100% externalisée ? - NEUTRE vs ACHAT, OC 0,13€ vs 0,17€ by Invest Securities
- Hongfa Technology (600885 CH) by HSBC
- Glodon (002410 CH) by HSBC
- VISCOFAN: 1Q’25 RESULTS (ANÁLISIS BANCO SABADELL) by Sabadell
- 泸州老窖（000568 CH） by HSBC
- Q1 25 prelims: Strong order intake in both RVS and CVS by BNP Paribas Exane
- Frasers Centrepoint Trust (FCT SP) by HSBC
- NHY, STRATEGY, FQM, SSAB, NUE, STEEL CHINA, STEEL US, PREVIEW, MT, APAM by BNP Paribas Exane
- Q125 conf. call: modest incremental positives by BNP Paribas Exane
- LatAm Insurance by HSBC